Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3985863 in healthy Chinese participants
NCT07030127Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2025
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Sarcopenia comparing LY3985863 with Placebo (2 arms). Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) at 19 weeks. Started Aug 2025; status: completed.
02
Drugs
bimagrumab
03
Conditions
obesitySarcopenia
Beyond the preview
Go deeper on NCT07030127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07030127.